ACINO

Dow combines global breadth, asset integration and scale, focused innovation, and leading business positions to achieve profitable growth. Our ambition is to become the most innovative, customer-centric, inclusive, and sustainable materials science company, with a purpose to deliver a sustainable future for the world through our materials science expertise and collaboration with our partners. Our portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility, and consumer care. We operate 106 manufacturing sites in 31 countries and employ approximately 35,700 people.

For more than 30 years, Faller Packaging has specialised in tailor-made, full-range solutions for secondary packaging materials for the pharmaceutical industry. The company is a single-source supplier that develops and manufactures folding cartons, package inserts, labels and combination products and delivers both standard products and special solutions based on customers’ wishes. Digitalised, optimally harmonised processes ensure maximum efficiency, sustainable production and fast, reliable delivery times. In addition, Faller offers customised logistics services and supply chain concepts. As a result, the company is an expert partner for everything relating to the procurement and packaging of pharmaceutical and healthcare products.

In addition to its headquarters in Waldkirch in the German state of Baden-Wuerttemberg, Faller Packaging also has sites in Binzen, Großbeeren and Schopfheim as well as in Hvidovre in Denmark and Łódź in Poland. The Worms-based subsidiary PackEx, which was founded in 2018, specialises in the manufacture of folding cartons in small and very small batches. In collaboration with the Irish company Perigord Premedia Ltd., Faller has set up a “Global Centre of Packaging Excellence” for artwork management, print consultancy and coordination. In total, August Faller GmbH & Co. KG has more than 1,300 employees.

Bactolac Pharmaceutical is a nutritional supplement manufacturer led by a team of experienced scientists and pharmacists. Founded in New York in 1995, the company’s goal has always been to provide high-quality vitamins and supplements at competitive prices to help customers become successful in the health and wellness supplementation market. A full-service health supplement manufacturer and vitamin supplier, we offer everything from product manufacturing to product testing, packaging, labeling, and distribution. These processes are all carried out in our high-tech, 350,000 square foot facility which houses innovative equipment and state-of-the-art laboratories. This facility is cGMP certified and meets all FDA requirements for nutritional supplement manufacturing. As a leading nutritional supplement manufacturer, Bactolac offers customers a wide variety of nutraceutical capsules, sublingual, soft gels, liquids, chewables, tablets, and powders for private label manufacturing.

Our company provides turnkey services to clients for the creation, production and marketing of nutritional supplements for large, medium and small sized businesses. Whether you’re looking to develop a single product or an entire product line, our technicians and scientists will provide the quality and service required from a high quality supplement manufacturer. Bactolac has been enabling our customers to reach their goals and is dedicated to giving you top quality products at affordable prices.

We invite you to visit Bactolac in person. We are happy to arrange a tour and meeting for our potential partners. Come see why Bactolac is the future of private label contract manufacturing for the vitamin and nutraceutical industry. Visit our website, www.bactolac.com for further information, or give us a call at 631-951-4908

Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. (AAI|CML) have merged to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation and analytical development, material testing, finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.

AAI|CML offers comprehensive services to expedite drug products through the full range of development – from early phase studies to full-scale (commercial) production of APIs and finished dosage forms. In addition to our development capabilities, our network of regional analytical testing laboratories located in St. Louis, MO; Edison, NJ; Durham, NC; and Wilmington, NC provides industry-leading turn-around-times.

CML has five centers of excellence: process chemistry, solid state chemistry, API manufacturing, analytical services, and quality assurance.

To learn more, visit www.aaipharma.com and www.c-mlabs.com.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products and associated Packaging Services. Through a network of cGMP facilities across Europe and the US organized under four technology platforms – Peptides, Lipids & Carbohydrates – Injectables - Highly Potent & Oncology - Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value products.

<< Peptides, Lipids & Carbohydrates >>

• Synthetic Peptide API Production
- Solid-phase, Liquid-phase, Hybrid Synthesis
- cGMP & non-cGMP
• Synthetic Lipids
• Carbohydrates

<< Sterile Injectables >>

• New Development & Commercial Suites for Aseptic Filling with > 60.000 units
per day (Pre-filled Syringes, Liquid or Lyophilized Vials)
• Packaging, Labeling & Logistics
• Sterile Emulsion Technology
• Large Pre-Filled Syringes
• Clinical Trial Services

<< Highly Potent & Oncology >>

• API Development & Commercial Manufacturing
(SafeBridge Category 4, OEL ≤1 ng/m3)
- New Development & Scale-up Capacity for Phase I/II Supply
• Drug Product Development & Manufacturing
- New Development Suite (CTD2) for Mid-scale Oral Dosage (up to 20 kg)
- Sterile Liquid & Lyophilization
- Primary & Secondary Packaging

<< Small Molecules >>

• Development & Commercial Manufacturing
- Intermediates
- APIs & Excipients
- Clinical Supply Phases I-III
• Proprietary & Generic Advanced Intermediates & APIs

Visit > www.cordenpharma.com